

Myasthenia Gravis Therapeutics Market - 2025-2033

<https://marketpublishers.com/r/MBD81C9D7362EN.html>

Date: April 2026

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: MBD81C9D7362EN

Abstracts

The Myasthenia Gravis Therapeutics Market was valued at USD 1.64 billion in 2025 and is anticipated to reach USD 3.48 billion by 2033, at a CAGR of 0.096 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Myasthenia Gravis Therapeutics Market.

This report delivers a comprehensive overview of the Myasthenia Gravis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Myasthenia Gravis Therapeutics Market. The Myasthenia Gravis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Myasthenia Gravis Therapeutics Market Scope:

By Type

Ocular myasthenia gravis

Congenital myasthenia gravis

Generalized myasthenia gravis

Transient myasthenia gravis

Others

By Treatment

Cholinesterase inhibitors

Immunosuppressive drugs

Plasmapheresis and intravenous immunoglobulin

Thymectomy

Other

By End-user

Hospital

Clinics

Others

Key Players

Alexion Pharmaceutical Inc.

Grifols SA

Avadel Pharmaceuticals plc.

Novartis AG

Pfizer, Inc.

AbbVie Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Bausch Health Companies Inc.

Shire plc.

Major Highlights

This report delivers a comprehensive overview of the Myasthenia Gravis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Myasthenia Gravis Therapeutics Market. The Myasthenia Gravis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Type
- 3.2. Market snippet by Treatment
- 3.3. Market Snippet by End-user
- 3.4. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
- 4.2. Drivers
 - 4.2.1. Rising Incidence of Myasthenia Gravis
 - 4.2.2. Increasing Research and Development for Myasthenia Gravis
- 4.3. Restraints:
 - 4.3.1. Adverse Effects associated with drugs
- 4.4. Opportunity
- 4.5. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Unmet Needs

6. BY TYPE

- 6.1. Introduction

- 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
- 6.1.2. Market Attractiveness Index, By Type Segment
- 6.2. Ocular myasthenia gravis*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 6.3. Congenital myasthenia gravis
- 6.4. Generalized myasthenia gravis
- 6.5. Transient myasthenia gravis
- 6.6. Others

7. BY TREATMENT

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
 - 7.1.2. Market Attractiveness Index, By Treatment
- 7.2. Cholinesterase inhibitors *
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3. Immunosuppressive drugs
- 7.4. Plasmapheresis and intravenous immunoglobulin
- 7.5. Thymectomy
- 7.6. Other

8. BY END-USER

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
 - 8.1.2. Market Attractiveness Index, By End-user Segment
- 8.2. Hospital *
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3. Clinics
- 8.4. Others

9. BY REGION

- 9.1. Introduction
- 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
- 9.3. Market Attractiveness Index, By Region

9.4. North America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. U.S.

9.4.6.2. Canada

9.4.6.3. Mexico

9.5. Europe

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. Germany

9.5.6.2. U.K.

9.5.6.3. France

9.5.6.4. Italy

9.5.6.5. Spain

9.5.6.6. Rest of Europe

9.6. South America

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.6.6.1. Brazil

9.6.6.2. Argentina

9.6.6.3. Rest of South America

9.7. Asia Pacific

9.7.1. Introduction

9.7.2. Key Region-Specific Dynamics

9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.7.6.1. China

9.7.6.2. India

9.7.6.3. Japan

9.7.6.4. Australia

9.7.6.5. Rest of Asia Pacific

9.8. Middle East and Africa

9.8.1. Introduction

9.8.2. Key Region-Specific Dynamics

9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment

9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Alexion Pharmaceutical Inc.*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. Grifols SA

11.3. Avadel Pharmaceuticals plc.

11.4. Novartis AG

11.5. Pfizer, Inc.

11.6. AbbVie Inc.

11.7. F. Hoffmann-La Roche Ltd.

11.8. GlaxoSmithKline plc

11.9. Bausch Health Companies Inc.

11.10. Shire plc. (List Not Exhaustive)

12. PREMIUM INSIGHTS

13. DATAM INTELLIGENCE

13.1. Appendix

13.2. About Us and Services

13.3. Contact Us

I would like to order

Product name: Myasthenia Gravis Therapeutics Market - 2025-2033

Product link: <https://marketpublishers.com/r/MBD81C9D7362EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MBD81C9D7362EN.html>